Introduction
The 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) was held in Orlando, Florida from May 29-June 2, 2009. The ultimate objective was to “focus on personalizing cancer care”. Experts from around the world met to announce and consider new experimental and clinical breast cancer data. This newsletter will highlight both adjuvant and metastatic disease information presented at the meeting, including significant findings in HER2-based therapies, EGFR-based therapies, antiangiogenic-based therapies, and triple negative disease, as well as therapies under investigation.
Editors
Maura N. Dickler, MD, bio | Francisco J. Esteva, MD, PhD, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours | Release date: July 2, 2009 | Expiration date: July 1, 2010
Statement of Need
Significant improvements have occurred in the management of women with breast cancer. As many of these advances are incorporated into the formulation of treatment guidelines, their dissemination to the medical oncology community is critical for their adaptation and potential to impact the long-term outcomes of these patients. Continuing medical education programs are important vehicles to assist in the timely distribution and application of this key information in order to improve patient outcomes.
Target Audience
The target audience for the program includes medical, surgical, and radiation oncologists, as well as allied oncology healthcare professionals charged with the care of patients with breast cancer.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Summarize the efficacy and safety results from key trials introducing use of novel agents and/or mechanisms
- Select appropriate chemotherapy/biologic combination regimens based on current understanding of clinical markers, efficacy, and safety profiles
- Describe advances in the development and integration of biologic therapies for the management of patients with breast cancer in novel disease settings and combinations
- Evaluate emerging new therapeutic options for treatment of breast cancer by reviewing ongoing and planned clinical trials
__________________________________________________________________________________________________________________________________ |
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
|
 |
| Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of Activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for
1.5 contact hours (0.15 CEUs) (UPN 199-000-09-037-H01-P). |
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity.
During the period July 2, 2009 through July 1, 2010, participants must 1) read
the learning objectives and faculty disclosures; 2) study the educational activity;
3) complete the post-test and activity evaluation form.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
DISCLOSURE OF CONFLICT OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Educational Concepts Group, LLC (ECG) does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE
Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681
Fax: 1.770.933.1692
www.educationalconcepts.net
None of the contents may be reproduced in any form without prior written permission
from the publisher. This activity may be accessed at www.educationalconcepts.net. |
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Maura N. Dickler, MD
Grants/Research Support
Abraxis BioScience, Genentech
Consultant Fees
Genentech, GlaxoSmithKline, Novartis, Pfizer Inc., Roche
Honorarium
Roche
Francisco J. Esteva, MD, PhD
No financial relationships to disclose
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Bristol-Myers Squibb Company, Genentech BioOncology, and sanofi-aventis Group.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
|
